Search results for: 'pace to point learning platform'
- Related search terms
- Point-of-Care Testing (POCT) Market
- Point-of-Care Testing Market, Global, 2024–2031
- Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026
- Point-of-Care Ultrasound Imaging Technology Ecosystem,
- Point-of-Care Ultrasound Imaging Technology Ecosystem, 2026.
-
11 Nov 2015  |  Asia Pacific  |  Market Research
Asia-Pacific Point-of-Care Testing Market
Trends, Challenges, and Best Practices for Stakeholders
Asia-Pacific (APAC) point-of-care testing (POCT) market was worth $2.80 billion in 2014. In hospitals, POC is used more in emergency rooms (ERs), operation theatres (OTs), recovery rooms (RRs), cath labs, and intensive care units (ICU). The rental model in which the cost of the device is borne by the manufacturer while the profit is shared by the h...
$4,950.00
Special Price $3,712.50 save 25 %
-
07 Jun 2019  |  Asia Pacific  |  Market Research
Growth Insights in APAC Infectious Disease Point-of-Care Testing (POCT) Market, Forecast to 2023
The Rising Prevalence of TB, HIV, and Hepatitis, Accompanied by the Development of Portable POCT Devices will Propel the APAC Infectious Diseases POCT Market
This study presents an overview of the Asia-Pacific infectious disease point-of-care testing (POCT) market with an emphasis on some of the key trends and growth opportunities that are shaping the market. The study highlights some of the emerging business models supporting the development and adoption of innovative diagnostic tests. The Asia-Pacif...
$3,000.00
Special Price $2,250.00 save 25 %
-
20 Apr 2023  |  Asia Pacific  |  Market Outlook
Asia-Pacific Next-generation Diagnostics Outlook, 2023
The Renewed Focus on Infectious Diseases Outside COVID-9, Oncology, Cardiovascular, Diabetes, and Prenatal Care will Drive Market Growth
The Asia-Pacific next-generation diagnostics market's revenue is projected to decline by 5.0% in 2023, attributed to the reduced demand for COVID-19-related testing. Rapid expansion in non-COVID molecular diagnostics and point-of-care testing (POCT) will not be sufficient to drive the overall recovery of the region. As companies continue to focus o...
$4,950.00
Special Price $3,712.50 save 25 %
-
20 May 2014  |  Asia Pacific  |  Market Research
Russia In Vitro Diagnostics (IVD) Market Data
Early Detection Provides New Opportunities for IVD Industry
This study provides data for the Russian in vitro diagnostics (IVD) market. Hematology, hemostasis (coagulation), urinalysis, microbiology, clinical chemistry, point of care testing, molecular diagnostics, immunochemistry, and others namely, tissue diagnostics and self-monitoring blood glucose, are the segments discussed in this market. Market reve...
$3,950.00
Special Price $2,962.50 save 25 %
-
23 Mar 2017  |  Asia Pacific  |  Market Research
APAC Molecular Diagnostics Market, Forecast to 2021
Pharmerging Economies with Rising Healthcare Demands will Accentuate Growth
The molecular diagnostics (MDx) market in APAC is witnessing rapid growth due to two main factors: the high adoption of MDx tests for infectious diseases applications in emerging countries, and the advent of innovative diagnostic solutions in cancer and NGS based solutions that are gaining pace in Asia. Multinational companies have not only identif...
$4,950.00
Special Price $3,712.50 save 25 %
-
19 Jun 2017  |  Asia Pacific  |  Market Research
Growth Opportunities in the APAC IVD Market, Forecast to 2021
Digital Pathology and Laboratory Automation are Two Strategic Themes Driving the Growth of the IVD Market
The study aims to analyze and forecast the Asia Pacific (APAC) in-vitro diagnostics (IVD) market outlook and technology trends for 2016. Research Scope: • Key trends and opportunities in the IVD market, which has been segmented into 8 major divisions: o Immunochemistry o Self-monitoring Blood Glucose (SMBG) Meter o Hematology o Point-of-care T...
$4,950.00
Special Price $3,712.50 save 25 %
-
10 Jan 2018  |  Asia Pacific  |  Market Research
APAC Biosimilar Market, Forecast 2025
Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth
Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Korea, o...
$4,950.00
Special Price $3,712.50 save 25 %